Instead of bringing its own products to market, the company will now seek to develop products and technologies on behalf of partners. Zyomyx will focus on proteomics, molecular diagnostic, medical devices, and other industrial applications of its expertise.
The company will also continue to offer existing protein array products through a "streamlined service model."
"Our expertise and intellectual property in protein chip technologies, bio-interfaces and micro-scale bio-analysis are substantial, and we intend to accelerate the process already underway of building alliances with partners and customers to apply" these technologies, Peter Wagner, the company's new CEO and former chief technology officer, said in a statement.
Zyomyx did acknowledge an auction of "surplus" equipment and a "new lean structure" but did not mention lay-offs specifically in its statement.